EYPT Profile
EyePoint Pharmaceuticals, Inc. is a specialized pharmaceutical company focused on developing and commercializing advanced therapeutics for serious eye disorders. The company’s portfolio includes YUTIQ, a treatment for chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, which addresses postoperative inflammation. Both products leverage EyePoint’s innovative Durasert technology, which provides sustained drug delivery directly to the eye, improving patient outcomes and convenience.
EyePoint Pharmaceuticals is advancing its pipeline with several investigational products based on its proprietary Durasert technology. Notably, EYP-1901, an investigational sustained delivery intravitreal treatment, is currently in Phase 2 clinical trials. This treatment aims to provide long-term management of retinal diseases, potentially reducing the need for frequent injections and improving adherence to therapy.
The company’s strategic focus is on leveraging its Durasert technology to address unmet needs in ophthalmology. This technology is designed to offer controlled and sustained release of medications directly to the eye, which can significantly enhance the efficacy and convenience of treatment for chronic and severe eye conditions.
Originally founded as pSivida Corp. in 2000, EyePoint Pharmaceuticals, Inc. underwent a rebranding to its current name in March 2018. Headquartered in Watertown, Massachusetts, the company continues to build on its legacy of innovation in eye care, with a commitment to improving the quality of life for patients through cutting-edge therapeutic solutions.
|
